On July 27, 2023, a bipartisan group of lawmakers issued a Request for Information (RFI) regarding the regulation of hemp-derived CBD products. The RFI seeks to evaluate the possibility of establishing a comprehensive regulatory framework for CBD. Congress seeks insights on CBD market dynamics, regulatory pathways, product scope, safety concerns, risk-benefit profiles, quality controls, and form, packaging, accessibility, and labeling. They also want to understand federal-state interactions, the impact of state programs on CBD regulation, and seek feedback on restrictions for consumer safety and responsible CBD use.
The Agriculture Improvement Act of 2018 removed hemp and hemp-derived CBD from the Controlled Substances Act, granting FDA authority to regulate CBD in FDA-regulated products. However, the FDA has maintained that CBD cannot be marketed as a food additive or dietary supplement under existing law. This RFI follows the FDA’s announcement of its intent to collaborate with Congress to devise a legislative strategy for CBD product regulation.
Stakeholders who are interested in submitting comments have the opportunity to provide their feedback until August 18, 2023. You can submit your comments to CBD@mail.house.gov or CBD@help.senate.gov.
Read the Request for Information.
Last Updated on August 8, 2023 by Aimed Alliance
